New hair loss cream shows promise in early trial
NCT ID NCT05802173
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a new drug called TDM-105795 for male pattern baldness. 71 men with mild to moderate hair loss applied a solution to their scalp every day for 16 weeks. The study measured hair count and hair width to see if the treatment helped regrow hair.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TDM-105795 (a topical solution applied to the scalp)
What this could lead to
If it works, this could point toward a new daily treatment to regrow hair in men with mild to moderate male pattern baldness.
What could go wrong
This is a small, early-phase trial with only 71 men, so results may not apply to everyone. The treatment is a topical solution that must be used daily, and it may not work for all types of hair loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA, ANDROGENETIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1
Austin, Texas, 78759, United States
-
Site 10
Minneapolis, Minnesota, 55455, United States
-
Site 11
Baton Rouge, Louisiana, 70809, United States
-
Site 12
North Little Rock, Arkansas, 72116, United States
-
Site 13
New Orleans, Louisiana, 70115, United States
-
Site 2
Norfolk, Virginia, 23502, United States
-
Site 3
Portland, Oregon, 97210, United States
-
Site 4
Rolling Meadows, Illinois, 60008, United States
-
Site 5
Knoxville, Tennessee, 37909, United States
-
Site 6
College Station, Texas, 77845, United States
-
Site 7
Plainfield, Indiana, 46168, United States
-
Site 8
Murfreesboro, Tennessee, 37130, United States
-
Site 9
New Brighton, Minnesota, 55112, United States